PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26021F0018Iclusig 45mg tablet&iclusig 15mg TABLET — Millennium Pharmaceuticals, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Jan 6, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Millennium Pharmaceuticals, Inc

Recipient

Jan 6, 2022

PoP end

$-103,519.8

Obligated

$198K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Millennium Pharmaceuticals, Inc — $90

Contract facts

Federal

Contract number36C26021F0018

Also listed as36C260-21-F-0018

Also listed as36F79718D0586-36C26021F0018

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentMillennium Pharmaceuticals, Inc

CAGE3FLV7

UEIENNFDLWFC6L1

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79718D0586

Place of performanceCAMBRIDGE MA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 1, 2020

PoP end (current)Jan 6, 2022

Obligated$-103,519.8

Current value$198K

Potential value$198K

ICLUSIG 45MG TABLET&ICLUSIG 15MG TABLET is a federal award for 260-Network Contract Office 20 (36C260) held by Millennium Pharmaceuticals, Inc. Estimated value $198K ($-103,519.8 obligated). Current period of performance ends Jan 6, 2022. Last award drew 1 bidder. Place of performance: CAMBRIDGE MA.

Recompete timing

Public

● Past PoP end (1689 days ago)

Current PoP ended Jan 6, 2022 (1689 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26021F0018?

36C26021F0018 (Iclusig 45mg tablet&iclusig 15mg TABLET) is a 260-Network Contract Office 20 (36C260) award with a potential value of $198K, currently held by Millennium Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-21-F-0018?

36C260-21-F-0018 is the dashed form of PIID 36C26021F0018 (Iclusig 45mg tablet&iclusig 15mg TABLET), held by Millennium Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26021F0018?

260-Network Contract Office 20 (36C260) awarded 36C26021F0018 to Millennium Pharmaceuticals, Inc (potential $198K).

Who is the incumbent on 36C26021F0018?

Millennium Pharmaceuticals, Inc is the incumbent. The current period of performance ends Jan 6, 2022.

When does Millennium Pharmaceuticals, Inc’s 36C26021F0018 come up for recompete?

SCOUT tracks a period-of-performance end of Jan 6, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jan 6, 2022 · refreshed monthly